相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
Stefano Fanti et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
The Role of Theranostics in Prostate Cancer
Elisabeth O'Dwyer et al.
SEMINARS IN RADIATION ONCOLOGY (2021)
The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up
Johanna Maffey-Steffan et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
John Violet et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy
Domenico Finocchiaro et al.
EJNMMI PHYSICS (2020)
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Eric Powers et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Alexander Heinzel et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy
Thomas W. Barber et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
Madhav Prasad Yadav et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2019)
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
Clemens Kratochwil et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics
Kambiz Rahbar et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
Bernhard Grubmueller et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
John Violet et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Delayed response after repeated Lu-177-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
Kambiz Rahbar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
Finn Edler von Eyben et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy
Anna Katharina Seitz et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq
Hendrik Rathke et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S. Hofman et al.
LANCET ONCOLOGY (2018)
Experimental validation of absolute SPECT/CT quantification for response monitoring in breast cancer
Angela Collarino et al.
MEDICAL PHYSICS (2018)
[177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
Thorsten Derlin et al.
LANCET ONCOLOGY (2018)
68Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature
Helle D. Zacho et al.
CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING (2018)
Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study
Manoj Gupta et al.
NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment
Madhav Prasad Yadav et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
Frederik L. Giesel et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
Wolfgang P. Fendler et al.
ONCOTARGET (2017)
Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?
Uta Eberlein et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223
O. Sartor et al.
ANNALS OF ONCOLOGY (2017)
Dosimetry for Lu-177-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer
Andreas Delker et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
Richard P. Baum et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0
Joo O. Hyun et al.
RADIOLOGY (2016)
Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks
A. Pfestroff et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study
Hojjat Ahmadzadehfar et al.
EJNMMI RESEARCH (2015)
Radium Ra 223 Dichloride Injection: US Food and Drug Administration Drug Approval Summary
Paul G. Kluetz et al.
CLINICAL CANCER RESEARCH (2014)
Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer
Martina Weineisen et al.
EJNMMI RESEARCH (2014)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
分享论文
